A distinct p53 target gene set predicts for response to the selective p53- HDM2 inhibitor NVP-CGM097

eLife

Volumn 4, Issue MAY, 2015, Pages

  Jeay, Sébastien ^a   Gaulis, Swann ^a   Ferretti, Stéphane ^a   Bitter, Hans ^b   Ito, Moriko ^a   Valat, Thérèse ^a   Murakami, Masato ^a   Ruetz, Stephan ^a   Guthy, Daniel A ^a   Rynn, Caroline ^a   Jensen, Michael R ^a   Wiesmann, Marion ^a   Kallen, Joerg ^a   Furet, Pascal ^a   Gessier, François ^a   Holzer, Philipp ^a   Masuya, Keiichi ^a,c   Würthner, Jens ^a   Halilovic, Ensar ^b   Hofmann, Francesco ^a   Sellers, William R ^b   Graus Porta, Diana ^a   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c PEPTIDREAM INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; NVP CFC218; NVP CGM097; PROTEIN INHIBITOR; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ISOQUINOLINE DERIVATIVE; MDM2 PROTEIN, HUMAN; NVP-CGM097; PIPERAZINE DERIVATIVE; PROTEIN MDM2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CARCINOMA; CELL PROLIFERATION; CELL VIABILITY; CLINICAL FEATURE; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION; ANTAGONISTS AND INHIBITORS; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; PATIENT SELECTION; TUMOR CELL LINE;

BIOMARKERS; CELL LINE, TUMOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOQUINOLINES; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930621854     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.06498     Document Type: Article

References (53)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
3. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
4. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
5. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010;17:93-102.
6. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
7. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
8. Picksley SM, Lane DP. The p53-mdm2 m2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 1993;15:689-90.
9. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
10. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
11. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5:3-8.
12. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
13. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-58.
14. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83.
15. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9:862-73.
16. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010;20:299-309.
17. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006;20:125-31.
18. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011;8:25-37.
19. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
20. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-53.
21. García-Echeverría C, Chène P, Blommers MJ, Furet P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 2000;43:3205-8.
22. Furet P, Chène P, De Pover A, Valat TS, Lisztwan JH, Kallen J, Masuya K. The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. Bioorg Med Chem Lett 2012;22:3498-502.
23. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
24. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
25. Miyashita T, Krajewski S, Krajewska M, Wang ang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
26. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 1994;13:4816-22.
27. Varmeh-Ziaie S, Okan I, Wang Y, Magnusson KP, Warthoe P, Strauss M, Wiman KG. Wig- 1, a new p53-induced gene encoding a zinc finger protein. Oncogene 1997;15:2699-704.
28. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-9.
29. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 2002;99:12985-90.
30. Liu G, Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 2002;21:7195-204.
31. Tan T, Chu G. p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 2002;22:3247-54.
32. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004;304:596-600.
33. He H, Sun Y. Ribosomal protein S27L is a direct p53 target that regulates apoptosis. Oncogene 2007;26:2707-16.
34. Kawase T, Ichikawa H, Ohta T, Nozaki N, Tashiro F, Ohki R, Taya Y. p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis. Oncogene 2008;27:3797-810.
35. Xiong X, Zhao Y, He H, Sun Y. Ribosomal al protein S27-like and S27 interplay with p53- MDM2 axis as a target, a substrate and a regulator. Oncogene 2011;30:1798-811.
36. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
37. Masuya K, Furet P, Stutz S, Holzer P, Pissot-Soldmann C, Buschmann N, Valat T, Ferretti S, Ruetz S, Rynn C, Berghausen J, Jacoby E, Lang M, Gabriel T, Hofmann F, Kallen J, Jeay S, Gessier F. Discovery of NVP-CGM097 as a novel Mdm2 inhibitor. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Cancer Res 2014;74:Abstract #DDT01-01.
38. Jeay S, Berghausen J, Buschmann N, Chène P, Cozens R, Erdmann D, Ferretti S, Furet P, Gabriel T, Gessier F, Graus-Porta D, Hofmann F, Holzer P, Ito M, Jacoby E, Jensen M, Kallen J, Lang M, Lisztwan J, Murakami M, Pissot-Soldermann C, Ruetz S, Rynn C, Sterker D, Stutz S, Valat T, Wiesmann M, Masuya K. Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Cancer Res 2014;74:Abstract #1797.
39. Valat T, Masuya K, Baysang F, Albrecht G, Buschmann N, Erdmann D, Furet P, Gabriel T, Gessier F, Hofmann F, Holzer P, Kallen J, Pissot-Solderman C, Stutz S, Chène P, Jeay S. Mechanistic study of NVP-CGM097: a potent, selective and species specific inhibitor of p53-Mdm2. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Cancer Res 2014;74:Abstract #1798.
40. Ferretti S, Berger M, Rebmann nn R, Santacroce F, Sterker D, Jensen M, Masuya K, Jeay S. NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Cancer Res 2014;74:Abstract #4638.
41. Anderson SJ, Lauritsen JP, Hartman MG, Foushee AM, Lefebvre JM, Shinton SA, Gerhardt B, Hardy RR, Oravecz T, Wiest DL. Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53- dependent checkpoint. Immunity 2007;26:759-772.
42. Zhang Y, Duc AC, Rao S, Sun XL, Bilbee AN, Rhodes M, Li Q, Kappes DJ, Rhodes J, Wiest DL. Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. Dev Cell 2013;24:411-25.
43. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009;137:413-31.
44. Tang HY, Zhao K, Pizzolato JF, Fonarev M, Langer JC, Manfredi JJ. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. J Biol Chem 1998;273:29156-63.
45. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001;8:57-69.
46. Espinosa JM, Verdun RE, Emerson BM. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 2003;12:1015-27.
47. Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman n JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL, Dowell RD, Espinosa JM. Global analysis of p53- regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife 2014;3:e02200.
48. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
49. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
50. Goldstein DR. Partition resampling and extrapolation averaging: approximation methods for quantifying gene expression in large numbers of short oligonucleotide arrays. Bioinformatics 2006;22:2364-72.
51. Katz S, Irizarry RA, Lin X, Tripputi M, Porter MW. A summarization approach for Affymetrix GeneChip data using a reference training set from a large, biologically diverse database. BMC Bioinformatics 2006;7:464.Harbron C, Chang KM, South MC. RefPlus: an R package extending the RMA Algorithm. Bioinformatics 2007;23:2493-4.
52. Frey BJ, Dueck D. Clustering by passing messages between data points. Science 2007;315:972-6.
53. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;57:1-2.